Functional Peptide Nanofibers with Unique Tumor Targeting and Enzyme-Induced Local Retention Properties

Overview

Journal Adv Funct Mater

Date 2018 Dec 4

PMID 30505260

Citations 17

Authors

Vanessa Bellat

Richard Ting

Teresa L Southard

Linda Vahdat

Henrik Molina

Joseph Fernandez

Omer Aras

Tracy Stokol

Benedict Law

Affiliations

Soon will be listed here.

Abstract

An effective tumoral delivery system should show minimal removal by the reticuloendothelial system (RES), promote tumor uptake and penetration, and minimize on-site clearance. This study reports the design and synthesis of advanced self-assembling peptide nanofiber precursor (NFP) analogues. The peptidic nature of NFP offers the design flexibility for on-demand customization with imaging agents and surface charges while maintaining a set size, allowing for real-time monitoring of kinetic and dynamic tumoral delivery by multimodal fluorescence/positron emission tomography/computed tomography (fluo/PET/CT) imaging, for formulation optimization. The optimized glutathione (GSH)-NFP displays a reduced capture by the RES as well as excellent tumor targeting and tissue invasion properties compared to naive NFP. Inside a tumor, GSH-NFP can structurally transform into ten times larger interfibril networks, serving as in situ depot that promotes weeks-long local retention. This nanofiber, which can further be designed to release the active pharmacophores within a tumor microenvironment, displays a superior therapeutic efficacy for inhibiting disease progression and improving the survival of animals bearing triple-negative breast cancer tumors compared to free drug and liposome formulation of the drug, in addition to a favorable toxicity profile.

Citing Articles

Peptides as Versatile Regulators in Cancer Immunotherapy: Recent Advances, Challenges, and Future Prospects.

Lei Y, Liu J, Bai Y, Zheng C, Wang D Pharmaceutics. 2025; 17(1).

PMID: 39861694 PMC: 11768547. DOI: 10.3390/pharmaceutics17010046.

Assembling a new generation of radiopharmaceuticals with supramolecular theranostics.

Moreno-Alcantar G, Drexler M, Casini A Nat Rev Chem. 2024; 8(12):893-914.

PMID: 39468298 DOI: 10.1038/s41570-024-00657-4.

Transformable self-delivered supramolecular nanomaterials combined with anti-PD-1 antibodies alleviate tumor immunosuppression to treat breast cancer with bone metastasis.

Liu X, Wang H, Li Z, Li J, He S, Hu C J Nanobiotechnology. 2024; 22(1):566.

PMID: 39272206 PMC: 11401275. DOI: 10.1186/s12951-024-02839-0.

Biological Activity of Natural and Synthetic Peptides as Anticancer Agents.

Bauso L, La Fauci V, Munao S, Bonfiglio D, Armeli A, Maimone N Int J Mol Sci. 2024; 25(13).

PMID: 39000371 PMC: 11242495. DOI: 10.3390/ijms25137264.

Intracellular Enzyme-Instructed Self-Assembly of Peptides (IEISAP) for Biomedical Applications.

Lin F, Jia C, Wu F Molecules. 2022; 27(19).

PMID: 36235094 PMC: 9571778. DOI: 10.3390/molecules27196557.

References

Law B, Quinti L, Choi Y, Weissleder R, Tung C . A mitochondrial targeted fusion peptide exhibits remarkable cytotoxicity. Mol Cancer Ther. 2006; 5(8):1944-9. DOI: 10.1158/1535-7163.MCT-05-0509. View

Huo S, Ma H, Huang K, Liu J, Wei T, Jin S . Superior penetration and retention behavior of 50 nm gold nanoparticles in tumors. Cancer Res. 2012; 73(1):319-30. DOI: 10.1158/0008-5472.CAN-12-2071. View

Greish K . Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting. Methods Mol Biol. 2010; 624:25-37. DOI: 10.1007/978-1-60761-609-2_3. View

Malik R, Qian S, Law B . Design and synthesis of a near-infrared fluorescent nanofiber precursor for detecting cell-secreted urokinase activity. Anal Biochem. 2011; 412(1):26-33. DOI: 10.1016/j.ab.2011.01.010. View

Nichols J, Bae Y . EPR: Evidence and fallacy. J Control Release. 2014; 190:451-64. DOI: 10.1016/j.jconrel.2014.03.057. View

Zeglis B, Lewis J . The bioconjugation and radiosynthesis of 89Zr-DFO-labeled antibodies. J Vis Exp. 2015; (96). PMC: 4354640. DOI: 10.3791/52521. View

Maeda H, Nakamura H, Fang J . The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv Drug Deliv Rev. 2012; 65(1):71-9. DOI: 10.1016/j.addr.2012.10.002. View

Smith B, Kempen P, Bouley D, Xu A, Liu Z, Melosh N . Shape matters: intravital microscopy reveals surprising geometrical dependence for nanoparticles in tumor models of extravasation. Nano Lett. 2012; 12(7):3369-77. PMC: 3495189. DOI: 10.1021/nl204175t. View

Zhang X, Luo Z, Chen J, Song S, Yuan X, Shen X . Ultrasmall glutathione-protected gold nanoclusters as next generation radiotherapy sensitizers with high tumor uptake and high renal clearance. Sci Rep. 2015; 5:8669. PMC: 4345316. DOI: 10.1038/srep08669. View

10.

Mukherjee S, Ray S, Thakur R . Solid lipid nanoparticles: a modern formulation approach in drug delivery system. Indian J Pharm Sci. 2010; 71(4):349-58. PMC: 2865805. DOI: 10.4103/0250-474X.57282. View

11.

Kong S, Zhang W, Lee J, Brammer K, Lal R, Karin M . Magnetically vectored nanocapsules for tumor penetration and remotely switchable on-demand drug release. Nano Lett. 2010; 10(12):5088-92. DOI: 10.1021/nl1033733. View

12.

Hu Q, Sun W, Lu Y, Bomba H, Ye Y, Jiang T . Tumor Microenvironment-Mediated Construction and Deconstruction of Extracellular Drug-Delivery Depots. Nano Lett. 2016; 16(2):1118-26. DOI: 10.1021/acs.nanolett.5b04343. View

13.

Leu A, Berk D, Lymboussaki A, Alitalo K, Jain R . Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. Cancer Res. 2000; 60(16):4324-7. View

14.

Prabaharan M, Grailer J, Pilla S, Steeber D, Gong S . Amphiphilic multi-arm-block copolymer conjugated with doxorubicin via pH-sensitive hydrazone bond for tumor-targeted drug delivery. Biomaterials. 2009; 30(29):5757-66. DOI: 10.1016/j.biomaterials.2009.07.020. View

15.

Morton C, Houghton P . Establishment of human tumor xenografts in immunodeficient mice. Nat Protoc. 2007; 2(2):247-50. DOI: 10.1038/nprot.2007.25. View

16.

Wang Y, Juan L, Ma X, Wang D, Ma H, Chang Y . Specific hemosiderin deposition in spleen induced by a low dose of cisplatin: altered iron metabolism and its implication as an acute hemosiderin formation model. Curr Drug Metab. 2010; 11(6):507-15. PMC: 2910113. DOI: 10.2174/138920010791636149. View

17.

Kang Y, Park D, Shin H, Park J, Kang S . Incorporation of thrombin cleavage peptide into a protein cage for constructing a protease-responsive multifunctional delivery nanoplatform. Biomacromolecules. 2012; 13(12):4057-64. DOI: 10.1021/bm301339s. View

18.

Sugahara K, Teesalu T, Karmali P, Kotamraju V, Agemy L, Greenwald D . Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science. 2010; 328(5981):1031-5. PMC: 2881692. DOI: 10.1126/science.1183057. View

19.

Trip A, Sikorska K, van Sandick J, Heeg M, Cats A, Boot H . Radiation-induced dose-dependent changes of the spleen following postoperative chemoradiotherapy for gastric cancer. Radiother Oncol. 2015; 116(2):239-44. DOI: 10.1016/j.radonc.2015.07.036. View

20.

Prabhakar U, Maeda H, Jain R, Sevick-Muraca E, Zamboni W, Farokhzad O . Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res. 2013; 73(8):2412-7. PMC: 3916009. DOI: 10.1158/0008-5472.CAN-12-4561. View